580 related articles for article (PubMed ID: 25579803)
1. A review of the evolution of systemic chemotherapy in the management of colorectal cancer.
Gustavsson B; Carlsson G; Machover D; Petrelli N; Roth A; Schmoll HJ; Tveit KM; Gibson F
Clin Colorectal Cancer; 2015 Mar; 14(1):1-10. PubMed ID: 25579803
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
3. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
[TBL] [Abstract][Full Text] [Related]
4. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
5. Current status of adjuvant therapy for colorectal cancer.
O'Connell MJ
Oncology (Williston Park); 2004 May; 18(6):751-5; discussion 755-8. PubMed ID: 15214594
[TBL] [Abstract][Full Text] [Related]
6. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
Lee JJ; Chu E
Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
8. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
[TBL] [Abstract][Full Text] [Related]
9. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
Hurwitz H
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S62-8. PubMed ID: 15479481
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
Medinger M; Steinbild S; Mross K
Praxis (Bern 1994); 2004 Sep; 93(40):1633-44. PubMed ID: 15495753
[TBL] [Abstract][Full Text] [Related]
11. Advances in the treatment of metastatic colorectal cancer.
Goldberg RM
Oncologist; 2005; 10 Suppl 3():40-8. PubMed ID: 16368870
[TBL] [Abstract][Full Text] [Related]
12. The future development of bevacizumab in colorectal cancer.
Díaz-Rubio E; Schmoll HJ
Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
[TBL] [Abstract][Full Text] [Related]
13. Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone.
Glimelius B; Stintzing S; Marshall J; Yoshino T; de Gramont A
Cancer Treat Rev; 2021 Jul; 98():102218. PubMed ID: 34015686
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer.
Moosmann N; Heinemann V
Expert Rev Anticancer Ther; 2008 Mar; 8(3):319-29. PubMed ID: 18366281
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
Grapsa D; Syrigos K; Saif MW
Expert Rev Anticancer Ther; 2015; 15(11):1267-81. PubMed ID: 26506906
[TBL] [Abstract][Full Text] [Related]
16. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
Zhao Z; Pelletier E; Barber B; Bhosle M; Wang S; Gao S; Klingman D
Curr Med Res Opin; 2012 Feb; 28(2):221-9. PubMed ID: 22171947
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
[TBL] [Abstract][Full Text] [Related]
18. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
19. New systemic frontline treatment for metastatic colorectal carcinoma.
Braun AH; Achterrath W; Wilke H; Vanhoefer U; Harstrick A; Preusser P
Cancer; 2004 Apr; 100(8):1558-77. PubMed ID: 15073842
[TBL] [Abstract][Full Text] [Related]
20. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]